Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

284P - Trastuzumab emtansine (T-DM1) in Asian patients with previously treated HER2-positive locally advanced (LA) or metastatic breast cancer (MBC): Data from the phase III EMILIA study

Date

16 Sep 2021

Session

ePoster Display

Presenters

Seock-Ah Im

Citation

Annals of Oncology (2021) 32 (suppl_5): S457-S515. 10.1016/annonc/annonc689

Authors

S. Im1, I. Park2, J.H. Sohn3, Y. Im4, S.C. Lee5, H. Chang6, H. Macharia7, G. Sun8, F. Lamour9, D. Oh10

Author affiliations

  • 1 Internal Medicine Dept, SNUH - Seoul National University Hospital, 03080 - Seoul/KR
  • 2 Department Of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul/KR
  • 3 Severence Hospital, Younsei University Health Center, Seoul/KR
  • 4 Department Of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul/KR
  • 5 Medical Oncology, National University of Singapore, 117599 - Singapore/SG
  • 6 Medical Oncology, National University of Singapore, Singapore/SG
  • 7 Oncology Biostatistics, F. Hoffmann-La Roche, Basel/CH
  • 8 Pdo, Roche (China) Holding Ltd., Shanghai/CN
  • 9 Pdo, F. Hoffmann-La Roche, Basel/CH
  • 10 Internal Medicine, Seoul National University, Seoul/KR
More

Abstract 284P

Background

The phase 3 EMILIA study (NCT00829166) was initiated based on phase 1 and 2 data identifying the HER2-targeted antibody-drug conjugate T-DM1 as a potential therapy for HER2-positive advanced breast cancer previously treated with trastuzumab (H) and taxane (T). We report a subgroup analysis of Asian patients enrolled in Asia.

Methods

EMILIA, a randomized, open-label, phase 3 study, compared T-DM1 (3.6 mg/kg IV q3w) with capecitabine (C; 1000 mg/m2 po bid, days 1–14, q3w) plus lapatinib (L; 1250 mg/day po qd) in patients with HT-pretreated HER2-positive, LA/MBC. Cox proportional hazards models and the Kaplan-Meier method were used to estimate progression-free (PFS) and overall survival (OS) in Asian patients.

Results

76 and 82 patients from Korea, Taiwan, Singapore, Hong Kong, and The Philippines were randomized to CL and T-DM1, respectively (75 and 80 were safety evaluable). At a median follow up of 13 months, median PFS was 6.9 vs 9.3 months (HR, 0.72; 95% CI: 0.48–1.06) with CL vs T-DM1. Objective response rates (modified RECIST v1.0) were 38.7% (95% CI: 26.7–51.9) and 44.4% (95% CI: 31.9–57.5) with CL and T-DM1 respectively, with median response durations of 6.9 and 9.6 months. At the 2nd interim analysis, with a median follow up of 19 months, median OS was 22.7 vs 34.3 months (HR, 0.43; 95% CI: 0.24–0.77) with CL vs T-DM1. There was an increase in G3-G4 thrombocytopenia in the Asian subgroup (Table); safety profiles were otherwise similar. Table: 284P

Adverse events(CTCAE v3.0; %) Global Asian
CL(n=488) T-DM1(n=490) CL(n=75) T-DM1(n=80)
≥Grade (G) 3 57.0 40.8 54.7 60.0
Leading to discontinuation C: 9.4L: 7.6 5.9 C: 4.0L: 1.3 6.3
ThrombocytopeniaG1G2G3G4 1.80.800.2 6.99.611.22.7 1.3000 3.85.030.58.8
HemorrhageG1G2G3G4 12.32.70.80 24.73.71.20.2 13.31.32.70 36.3000

Conclusions

T-DM1 conferred a clinically meaningful benefit compared with CL in Asian patients with HT-pretreated HER2-positive LA/MBC, which was generally consistent with that in the global population. Although generally similar to the global safety profile, increased G3 and G4 thrombocytopenia was noted with T-DM1 in Asian patients but there was no G>1 hemorrhage.

Clinical trial identification

NCT00829166.

Editorial acknowledgement

Medical writing support was provided by Tracy McNally, PhD, and Holly Strausbaugh, PhD, on behalf of Twist Medical, LLC, and funded by F. Hoffmann-La Roche, Ltd.

Legal entity responsible for the study

F. Hoffmann-La Roche Ltd.

Funding

F. Hoffmann-La Roche Ltd.

Disclosure

S. Im: Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: Amgen; Financial Interests, Personal, Advisory Board: Eisai; Financial Interests, Personal, Advisory Board: Hanmi; Financial Interests, Personal, Advisory Board: Lilly; Financial Interests, Personal, Advisory Board: Novartis; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Advisory Board: Roche; Non-Financial Interests, Personal, Other, Investigational agent for trial: Dae Woong; Financial Interests, Personal, Advisory Board: GSK. I. Park: Financial Interests, Personal, Full or part-time Employment: Korea University Guro hospital National Cancer Center, Korea. J.H. Sohn: Financial Interests, Institutional, Research Grant: MSD; Financial Interests, Institutional, Research Grant: Roche; Financial Interests, Institutional, Research Grant: Novartis; Financial Interests, Institutional, Research Grant: AstraZeneca; Financial Interests, Institutional, Research Grant: Lilly; Financial Interests, Institutional, Research Grant: Pfizer; Financial Interests, Institutional, Research Grant: GSK; Financial Interests, Institutional, Research Grant: Daiichi Sankyo; Financial Interests, Institutional, Research Grant: Sanofi; Financial Interests, Institutional, Research Grant: Boehringer Ingelheim. S.C. Lee: Financial Interests, Personal and Institutional, Invited Speaker: Pfizer; Financial Interests, Personal and Institutional, Advisory Board: Pfizer; Financial Interests, Personal and Institutional, Funding, research funding: Pfizer; Financial Interests, Personal and Institutional, Other, clinical trial drug support: Pfizer; Financial Interests, Personal and Institutional, Other, conference/travel support: Pfizer; Financial Interests, Personal and Institutional, Invited Speaker: Novartis; Financial Interests, Personal and Institutional, Advisory Board: Novartis; Financial Interests, Personal and Institutional, Advisory Board: Eli Lilly; Financial Interests, Personal and Institutional, Invited Speaker: Eisai; Financial Interests, Personal and Institutional, Advisory Board: Eisai; Financial Interests, Personal and Institutional, Other, clinical trial drug support: Eisai; Financial Interests, Personal and Institutional, Funding, research funding: Eisai; Financial Interests, Personal and Institutional, Other, clinical trial drug support: Taiho; Financial Interests, Personal and Institutional, Invited Speaker: AstraZeneca; Financial Interests, Personal and Institutional, Advisory Board: AstraZeneca; Financial Interests, Personal and Institutional, Other, educational grants: AstraZeneca; Financial Interests, Personal and Institutional, Funding, research funding: Bayer; Financial Interests, Personal and Institutional, Invited Speaker: ACT Genomics; Financial Interests, Personal and Institutional, Funding, research funding: ACT Genomics; Financial Interests, Personal and Institutional, Advisory Board: Roche; Financial Interests, Personal and Institutional, Other, educational grant: Roche; Financial Interests, Personal and Institutional, Advisory Board: MSD; Financial Interests, Personal and Institutional, Officer, conference/travel support: MSD; Financial Interests, Personal and Institutional, Other, conference/travel support: Amgen; Financial Interests, Personal and Institutional, Other, clinical trial drug support: Karyopharm; Financial Interests, Personal and Institutional, Other, research funding: Karyopharm. H. Chang: Financial Interests, Personal, Full or part-time Employment: Chang Gung Memorial Hospital; Non-Financial Interests, Personal, Invited Speaker: Chang Gung Memorial Hospital; Non-Financial Interests, Personal, Principal Investigator: Chang Gung Memorial Hospital; Non-Financial Interests, Personal, Advisory Role: Chang Gung Memorial Hospital. H. Macharia: Financial Interests, Personal, Full or part-time Employment: F. Hoffmann-La Roche. G. Sun: Financial Interests, Personal, Full or part-time Employment: F. Hoffmann-La Roche Ltd. F. Lamour: Financial Interests, Personal, Full or part-time Employment: F. Hoffmann-La Roche Ltd. D. Oh: Financial Interests, Personal, Advisory Board, Consultant: AstraZeneca; Financial Interests, Personal, Advisory Board, Consultant: Novartis; Financial Interests, Personal, Advisory Board, Consultant: Genentech/Roche; Financial Interests, Personal, Advisory Board, Consultant: Merck Serono; Financial Interests, Personal, Advisory Board, Consultant: Bayer; Financial Interests, Personal, Advisory Board, Consultant: Taiho; Financial Interests, Personal, Advisory Board, Consultant: ASLAN; Financial Interests, Personal, Advisory Board, Consultant: Halozyme; Financial Interests, Personal, Advisory Board, Consultant: Zymeworks; Financial Interests, Personal, Advisory Board, Consultant: BMS/Celgene; Financial Interests, Personal, Advisory Board, Consultant: BeiGene; Financial Interests, Personal, Advisory Board, Consultant: Basilea; Financial Interests, Personal, Advisory Board, Consultant: Turning Point; Financial Interests, Institutional, Research Grant: AstraZeneca; Financial Interests, Institutional, Research Grant: Novartis; Financial Interests, Institutional, Research Grant: Array; Financial Interests, Institutional, Research Grant: Eli Lilly; Financial Interests, Institutional, Research Grant: Servier; Financial Interests, Institutional, Research Grant: BeiGene; Financial Interests, Institutional, Research Grant: MSD; Financial Interests, Institutional, Research Grant: Handok. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.